Laurus Labs Limited — Governance Information 2021

Feb 10, 2021

LAURUS LABS LIMITED

==> picture [114 x 37] intentionally omitted <==

Laurus Labs wins coveted Golden Peacock Award for Excellence in Corporate Governance

Hyderabad, 10 February 2021 : Hyderabad-based Laurus Labs has won the prestigious Golden Peacock Award for Excellence in Corporate Governance 2020. Instituted in 1991 by the Institute of Directors (IOD), India, the Golden Peacock Award is regarded as a global stamp of Corporate Excellence. This is the first year that Laurus Labs has won this coveted award.

Speaking about this, Dr. Satyanarayana Chava, Founder & CEO said, “ This award is a testament to our consistent efforts to adhere to the highest standards in corporate governance and organizational practices in the pharmaceutical sector. It is a great honour to be one amongst other distinguished companies that have received this award this year .”

==> picture [119 x 127] intentionally omitted <==

. The Chairman of this year’s award jury was the Hon’ble Justice M. N. Venkatachaliah, former Chief Justice of India and former Chairman, National Human Rights Commission of India and National Commission for Constitution of India Reforms.

Unlike previous years, there was no physical ceremony for the award function this year. Laurus Labs, along with other winners, was felicitated during an online ceremony that was attended by several business leaders and participants from across the globe.

-ENDS-

About Laurus Labs Limited

Laurus Labs is a leading research-driven Pharmaceutical Manufacturing Company in India. We have grown to become one of the leading manufacturers of API for Anti-Retroviral (ARV), Oncology, Cardiovascular, Anti-Diabetics, Anti-Asthma, and Gastroenterology. We are thriving on growth opportunities in formulation manufacturing to service all leading markets of North America, Europe, and Low Middle-Income Countries (LMIC). We are driving growth opportunities in Contract Development and Manufacturing through our Synthesis business. Most of our manufacturing facilities approved by major regulatory authorities, USFDA, WHO-Geneva, UK-MHRA, etc. Our approach remains to identify and invest ahead of time with strategic investments in Stateof-the-Art R&D and Manufacturing Infrastructure enabling us to become a quality supplier of high volume products. Corporate Identification No: L24239AP2005PLC047518

For more information about us, please visit http://www.lauruslabs.com or Contact particulars:

Pavan Kumar N Laurus Labs Ltd. Tel: +91 40 6659 4380 Email: mediarelations@lauruslabs.com, pavankumar.n@lauruslabs.com

==> picture [62 x 53] intentionally omitted <==

==> picture [55 x 57] intentionally omitted <==

DISCLAIMER: Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Laurus Labs Limited (Laurus) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

FEBRAUARY 10, 2021

Press Release